a pill with no food restrictions and no cold chain changes this entire site
Flairing this Speculation because that is what it is. Orforglipron is a small molecule, not a peptide. ATTAIN-1 and ACHIEVE-1 (both NEJM , 2025) reported the efficacy numbers everyone quotes, but the interesting property is not the percentage. It is that a non-peptide oral escapes the absorption problem that makes…
The analytical half of this is a bigger change than people assume. Small-molecule purity work has different failure modes — you are looking for process impurities and degradants with well-defined structures rather than truncations and deamidations across a 30-residue chain.
It is also, generally, easier and cheaper to characterise. Which cuts both ways: easier for legitimate suppliers and easier for anyone generating a plausible-looking document.
i had not thought about the forgery side. a simpler assay is a simpler thing to fake convincingly.
and the community has three years of pattern-matching built on peptide documents. we would be starting again on the tells.
the nine patterns are mostly about documents and behaviour rather than chemistry, so i think most of them port. the chemistry-specific ones would not.
fair. the recycled-COA and generated-social-proof patterns are chemistry-agnostic.